PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.49%
Revenue growth under 50% of MCHP's 21.77%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
6.95%
Gross profit growth under 50% of MCHP's 34.65%. Michael Burry would be concerned about a severe competitive disadvantage.
39.71%
EBIT growth 50-75% of MCHP's 67.74%. Martin Whitman would suspect suboptimal resource allocation.
39.71%
Operating income growth at 50-75% of MCHP's 67.74%. Martin Whitman would doubt the firm’s ability to compete efficiently.
37.31%
Net income growth 1.25-1.5x MCHP's 27.59%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
33.33%
EPS growth of 33.33% while MCHP is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
33.33%
Diluted EPS growth of 33.33% while MCHP is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
0.82%
Slight or no buybacks while MCHP is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.55%
Slight or no buyback while MCHP is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-0.81%
Dividend reduction while MCHP stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-29.54%
Negative OCF growth while MCHP is at 79.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-82.21%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
65.84%
10Y CAGR of 65.84% while MCHP is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
35.07%
5Y CAGR of 35.07% while MCHP is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
26.89%
3Y CAGR of 26.89% while MCHP is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1140.12%
3Y OCF/share CAGR of 1140.12% while MCHP is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
1129.69%
10Y net income/share CAGR of 1129.69% while MCHP is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
52.11%
Net income/share CAGR of 52.11% while MCHP is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
199.89%
3Y net income/share CAGR of 199.89% while MCHP is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.43%
Equity/share CAGR of 16.43% while MCHP is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
10.94%
Dividend/share CAGR of 10.94% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
2.72%
Dividend/share CAGR of 2.72% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-88.41%
Negative near-term dividend growth while MCHP invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
7.11%
AR growth well above MCHP's 7.88%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.86%
Inventory growth well above MCHP's 6.60%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.78%
Asset growth well under 50% of MCHP's 17.93%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
6.90%
50-75% of MCHP's 10.99%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-1.41%
We’re deleveraging while MCHP stands at 25.68%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
We cut SG&A while MCHP invests at 28.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.